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Background: Painful Diabetic Neuropathy (PDN) is a debilitating syndrome present in a quarter of diabetic patients
that has a substantial impact on their quality of life. Despite this significant prevalence and impact, current
therapies for PDN are only partially effective. Moreover, the cellular mechanisms underlying PDN are not well
understood. Neuropathic pain is caused by a variety of phenomena including sustained excitability in sensory
neurons that reduces the pain threshold so that pain is produced in the absence of appropriate stimuli. Chemokine
signaling has been implicated in the pathogenesis of neuropathic pain in a variety of animal models. We therefore
tested the hypothesis that chemokine signaling mediates DRG neuronal hyperexcitability in association with PDN.
Results: We demonstrated that intraperitoneal administration of the specific CXCR4 antagonist AMD3100 reversed
PDN in two animal models of type II diabetes. Furthermore DRG sensory neurons acutely isolated from diabetic
mice displayed enhanced SDF-1 induced calcium responses. Moreover, we demonstrated that CXCR4 receptors are
expressed by a subset of DRG sensory neurons. Finally, we observed numerous CXCR4 expressing inflammatory cells
infiltrating into the DRG of diabetic mice.
Conclusions: These data suggest that CXCR4/SDF-1 signaling mediates enhanced calcium influx and excitability in
DRG neurons responsible for PDN. Simultaneously, CXCR4/SDF-1 signaling may coordinate inflammation in diabetic
DRG that could contribute to the development of pain in diabetes. Therefore, targeting CXCR4 chemokine
receptors may represent a novel intervention for treating PDN.
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Neuropathic pain in diabetes, Painful Diabetic Neuropathy
(PDN), is a debilitating affliction present in 26% of diabetic
patients [1-3] with substantial impact on their quality of
life [4]. Despite this significant prevalence and impact,
current therapies for PDN are only partially effective.
Moreover, the molecular and electrophysiological mec-
hanisms underlying PDN are not well understood.
This lack of understanding of the pathogenesis and the
molecular mechanisms underlying neuropathic pain rep-
resents a barrier to further progress in this field as empha-
sized by the failure of numerous potential therapeutic
approaches to successfully treat PDN. Opiates are not par-
ticularly effective in treating neuropathic pain and given* Correspondence: d-menichella@md.northwestern.edu
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distribution, and reproduction in any mediumthe chronic nature of this syndrome their use is proble-
matic [3]. Other drugs, such as gabapentinoids and antide-
pressants, do produce limited relief in some patients but
the presence of significant side effects and their lack of
effectiveness in many patients [5,6] means that better
therapeutic approaches are urgently needed. Given the
prevalence of PDN and the absence of effective therap-
ies we wanted to elucidate the molecular and physio-
logical mechanisms responsible for PDN as a critical
step towards developing more effective targeted thera-
peutic interventions in this disorder.
Pain is a physiological response to potentially dangerous
noxious stimuli. However, pathological or “neuropathic
pain” is associated with sustained excitability of sensory
neurons within pain pathways leading to reduced noci-
ceptive thresholds and the development of pathological
spontaneous activity, so that pain is produced in the
absence of appropriate stimuli [7-9]. The moleculartral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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sensory neurons leading to neuropathic pain are mostly
unknown. However, Dorsal Root Ganglia (DRG) sensory
neurons develop pathological spontaneous activity in re-
sponse to different molecules such as inflammatory cyto-
kines and chemokines [10-14].
Chemokines, or chemotactic cytokines, are a large group
of proteins important for the regulation of leukocyte migra-
tion [15,16]. In the last decade, numerous studies have
demonstrated that, in addition to their role in coordinating
the immune response, chemokines have important func-
tions in the nervous system [17]. For example, excita-
tory chemokine signaling has been implicated in the
pathogenesis of neuropathic pain in several animal models
[18]. In particular, some reports have implicated the che-
mokine stromal cell derived factor 1 (SDF-1) and its re-
ceptor CXCR4 in the pathogenesis of neuropathic pain in
a subset of animal models including HIV-1 induced neur-
opathy [19,20] and opiate induced hyperalgesia [21]. Im-
portantly, CXCR4 receptor expression as measured by
microarray analysis was increased in peripheral nerve
samples from diabetic patients with progressive diabetic
neuropathy [22], suggesting a similar role for CXCR4 re-
ceptors in PDN.
Based on this evidence, we hypothesized that excita-
tory CXCR4/SDF-1 signaling in DRG neurons may play
a critical role in the pathogenesis of PDN.
We now demonstrate that administration of a selective
CXCR4 antagonist, AMD3100, substantially reverses
neuropathic pain in animal models of type II diabetes.
These results indicate that CXCR4 mediated signaling is
necessary for PDN in mice. This hypothesis is consistent
with the expression of CXCR4 by a subpopulation of
DRG neurons and increased excitatory effects of the
chemokine SDF-1 on diabetic DRG neurons in culture.
Additionally, we observed numerous CXCR4 expressing
inflammatory cells infiltrating the DRG of diabetic mice.
Overall, these data suggest that CXCR4/SDF-1 signaling
mediates enhanced calcium influx and excitability in DRG
neurons responsible for PDN. CXCR4/SDF-1 signaling
may simultaneously coordinate inflammation in diabetic
DRG that could contribute to the development of pain
in diabetes. Therefore, CXCR4 signaling may constitute
a novel target for therapeutic intervention to PDN.
Results
The specific CXCR4 antagonist AMD3100 reverses
neuropathic pain in two animal models of type-II diabetes
In our first series of experiments we set up a model of
type II diabetes by feeding mice with a High Fat Diet
(HFD) for 10 weeks. These mice exhibited a gain in weight
and became glucose intolerant indicating the development
of diabetes (Table 1). Mice fed with a regular diet (RD) did
not develop diabetes. In order to examine whether HFDdiabetic mice also displayed signs of pain hypersensitivity,
pain behavior was assessed using Von-Frey filaments. We
observed that in HFD diabetic mice the withdrawal
threshold required to elicit a response was significantly re-
duced compared with RD non-diabetic mice, demonstra-
ting the development of neuropathic pain. Statistical
analysis revealed that the 50% threshold was 0.223 gram (g)
with SE 0.015 in HFD mice (n = 8) compared to 1.182 g
with SE 0.048 in RD mice (n = 8) (p < 0.001) (Figure 1).
In order to determine whether SDF-1/CXCR4 signaling
played a role in this behavior we examined the effects of
blocking CXCR4 receptors on pain behavior in this model
of type II diabetes. The highly selective CXCR4 chemokine
receptor antagonist AMD3100 was administered at a
concentration of 5 mg/kg, given as a single intraperitoneal
(i.p.) injection. We elected to use this concentration of
AMD3100 as we have previously demonstrated it to be ef-
fective in other animal models of neuropathic pain
[19,20]. Von Frey behavioral studies for mechanical allo-
dynia were repeated at 2 and 24 hours after AMD 3100
administration. These times points were elected as we had
already demonstrated that AMD3100 effectively reversed
neuropathic pain in other animal models one hour after
intraperitoneal injection [19,20].
These experiments demonstrated that AMD3100 sub-
stantially reversed neuropathic pain in HFD diabetic
mice. Indeed, 2 hours after antagonist injection in HFD
diabetic mice the paw withdrawal threshold increased sig-
nificantly compared with HFD induced diabetic mouse
injected with saline. Statistical analysis revealed that the
50% threshold was 1.001 g with SE 0.07 in HFD diabetic
mice injected with ADM3100 (n = 8) compared to 0.157 g
with SE 0.013 in HFD diabetic mice injected with saline
(n = 8). Values are expressed as means +/− SE (p <0.001)
(Figure 1A). After 24 hours this effect was no longer ap-
parent (Figure 1A). In contrast a selective CCR2 che-
mokine receptor blocking drug only minimally reversed
allodynia in HFD induced diabetic mice. Statistical ana-
lysis revealed that the 50% threshold was 0.302 g with
SE 0.024 in HFD diabetic mice injected with CCR2
antagonist (n = 6) compared to 0.174 g with SE 0.019 in
HFD diabetic mice injected with saline (n = 8). Values are
expressed as means +/− SE (p <0.001). This result differs
from some other pain models our laboratory has investi-
gated such as in osteoarthritis where CCR2 receptor dele-
tion or CCR2 receptor antagonists are much more effective
in ameliorating pain [23].
In order to confirm our findings in an additional model
of type II diabetes we repeated the same set of experi-
ments in a second well characterized model in which mice
carry a leptin receptor null mutation: the C57BLKS db/db
(db/db) mouse line. Db/db mice are known to display
mechanical allodynia after 6 weeks of age [24]. In keeping
with these previous reports, we observed that 18 weeks
Table 1 Glucose tolerance test (GTT) and weight of wild-type mice on high-fat-diet (WT HFD) and wild-type mice on
regular diet (WT RD)
Experimental animals Weight (g) Fasting glucose (mg/dl) 30 mins GTT (mg/dl) 60 mins GTT (mg/dl) 120 mins GTT (mg/dl)
WT HFD 34.0 +/− 0.8 112.2 +/− 4.7 465.1 +/− 13.9 444.9 +/− 18.0 264.7 +/− 14.0
WT RD 26.9 +/− 0.4 89.3 +/− 4.4 217.0 +/− 17.9 188.5 +/− 4.4 161.3 +/− 8.5
Value is expressed as mean+/− S.E.; p-value determined by two tailed Student’s t-testing with significance at p<.001.
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(Figure 1B). Von Frey behavioral studies for mechan-
ical allodynia were repeated at 2 and 24 hours after
AMD3100 administration at a concentration of 5 mg/
kg, given as a single intraperitoneal injection (i.p.).
These experiments demonstrated that AMD3100 also
substantially reversed neuropathic pain in homozygous
db/db mice at 2 but not 24 hours after administration
of the drug. Statistical analysis revealed that the 50%
threshold was 1.637 g with SE 0.084 in db/db injected
with AMD3100 (n = 8) compared with 0.320 g with SE
0.021 in db/db mice injected with saline (n = 8). Values
are expressed as means +/− SE (p <0.001) (Figure 1B).
Overall this first series of experiments demonstrated
that SDF-1/CXCR4 signaling is necessary for the ex-
pression of pain hypersensitivity in two separate animal
models of type II diabetes. As a result of these obser-
vations we next wanted to investigate the status of exci-
tatory CXCR4/SDF-1 signaling in DRG neurons taken
from diabetic animals.Figure 1 The specific CXCR4 antagonist, AMD3100, reversed neuropa
type (wt) mice on Regular Diet (RD) injected with saline (n = 8), (2) wt on RD
on High Fat Diet (HFD) injected with saline (n = 8); (4) Diabetic wt on HFD inj
test prior (0), 2hrs (2) and 24 hrs (24) after antagonist or saline injection. In dia
threshold was significantly reduced compared with wt on RD (1) demonstrati
antagonist injection in wt HFD (4) at 2hrs after injection (2) paw withdrawal th
receptors reversed neuropathic pain in HFD induced diabetic mice. At 24hrs (
not show any change. B. Experimental animal: (5) Control db-db heterozygou
homozygous (db/db) mice injected with saline (n = 8) (7) Diabetic db/db mic
antagonist injection the withdrawal threshold was significantly reduced comp
db/db model of type II diabetes. Following CXCR4 antagonist injection in diab
increases significantly, demonstrating that blocking CXCR4 receptor reverse n
injected with AMD3100 (5) did not show any change. Values are expressed asEnhanced SDF-1 induced increases in intracellular calcium
concentrations [Ca2+]i in HFD induced diabetic DRG neurons
One way that chemokine signaling could contribute to
chronic pain is by directly exciting DRG neurons, some-
thing that is associated with increases in neuronal [Ca2+]i
[25]. Our laboratory and others have already shown that
activation of CXCR4 receptors by its cognate ligand, the
chemokine SDF-1, results in excitation of DRG sensory
neurons and in increased [Ca2+]i in some animal models
of neuropathic pain [11]. Using [Ca2+]i imaging it is pos-
sible to test for the presence of functional receptors as
well as other properties of the neurons concerned. We
observed that application of SDF-1 increased [Ca2+]i
in DRG sensory neurons from HFD mice (Figure 2B),
although it did so much less frequently in non-diabetic
animals on a regular diet (Figure 2A). Statistical analysis
revealed that upon application of SDF-1, 89 ± 3.766% of
DRG neurons from HFD diabetic mice increased [Ca2+]i
(n = 140) compared to 27 ± 2.680% in RD (n = 140). Values
are expressed as means ± SE% (p <0.001).thic pain in type II diabetic mice. A. Experimental animals: (1) wild
injected with CXCR4 antagonist, AMD3100 (n = 8), (3) Diabetic wt mice
ected with AMD3100 (n = 8). Pain behavior was assessed using Von Frey
betic wt mice on HFD (3) prior to antagonist injection the withdrawal
ng neuropathic pain in HFD induced diabetes. Following CXCR4
reshold increases significantly demonstrating that blocking CXCR4
24) this effect was absent. Wt mice on HFD injected with saline (3) did
s (db het) mice injected with AMD3100 (n = 6), (6) Diabetic db-db
e injected with AMD3100 (n = 8). In diabetic db/db mice (6) prior to
ared with control db het mice, demonstrating neuropathic pain in the
etic db/db mice (7) at 2hrs after injection (2) paw withdrawal threshold
europathic pain in db-db model of type II diabetes. Db het control mice
mean+/− S.E. (p < 0.001).
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(MCP-1) was also applied. However, the percentage of
DRG sensory neurons responding to MCP-1 was not statis-
tically different in RD and HFD mice (data not shown). For
all experiments capsaicin, high K + (50 mM) and ATP were
added to assess the cell’s identity and viability, respectively.
A response to high K + stimulation indicates the presence
of voltage dependent Ca2+ channels, which is indicative
of neurons. Additionally, a positive response to capsaicin
as well as high K + indicates the cell is a nociceptor of the
subtype expressing the TRPV1 channel. A response to
ATP, which activates purinergic receptors, in the absence
of a response to high K + and/or capsaicin, indicates a
non-neuronal cell, presumably a type of glial cell such as a
satellite glial cell or Schwann cell. According to these cri-
teria all of the cells that responded to either SDF-1 or
MCP-1 were neurons. (Figure 2).
These results indicate that a increased number DRG
neurons express functional CXCR4 receptors in diabetic
mice and suggest that increased excitatory CXCR4/SDF-
1 signaling in DRG neurons could contribute to PDN.
CXCR4/SDF-1 signaling in diabetic DRG sensory neurons
Extensive characterization of DRG neurons has revealed
the existence of molecularly and functionally defined sub-
populations of cells. According to one type of classification
following sensory neurogenesis prospective DRG nocicep-
tive neurons undergo two distinct differentiation pathways
leading to the formation two major classes of molecularly
defined DRG neurons: 1) TrKA positive sensory neurons,
also known as “peptidergic” neurons which express Calci-
tonin Gene Related Peptide (CGRP) or Substance P and 2)
Ret positive sensory neurons also known as “non-peptider-
gic” neurons, first identified for their ability to bind isolectin
IB4 [26]. These two sets of DRG sensory neurons express
distinct populations of ion channels and receptors [26,27]
and carry different pain modalities [27,28]. Therefore, it is
important to determine which subpopulation of molecu-
larly defined DRG neurons expresses CXCR4 receptors.Figure 2 Application of the chemokine SDF-1 increased intracellular c
diabetes. Representative trace of intracellular calcium responses of acutely
indicating a response to SDF-1 in diabetic DRG. Response to high K + (50 m
HFD DRG (B).In order to define CXCR4 expression by DRG neu-
rons, we used mice in which the fluorescent protein
eGFP is expressed under the control of the CXCR4
promoter (CXCR4-eGFP mice). Confocal analysis of
DRG neurons in non-diabetic CXCR4-eGFP mice
showed that CXCR4-eGFP was expressed in a subset
of non-peptidergic (IB4 positive) but not in pep-
tidergic (CGRP positive) DRG neurons (Figure 3A-H).
Interestingly, CXCR4-eGFP reporter gene transcrip-
tional activity was clearly decreased in HFD induced
diabetic DRG (Figure 3I-P). Indeed, the percentage of IB4
positive DRG neurons expressing CXCR4-eGFP was
dramatically reduced in HFD induced mice compared
to RD non-diabetic mice (quantification in figure legend,
Figure 3I-P).
The expression of CXCR4 receptors was also investi-
gated using in situ localization of CXCR4 mRNA.
These experiments showed that some DRG neurons
normally exhibited very high levels of CXCR4 mRNA
(Figure 4C). In situ micrographs demonstrated that
very few neurons from HFD animals expressed high
levels of CXCR4 mRNA. Interestingly, however, there
was an increased number of neurons in HFD animals
that expressed lower levels of CXCR4 receptor mRNA
(Figure 4B). Quantification of DRG neurons express-
ing CXCR4 receptors revealed that overall the total
number of DRG neurons expressing CXCR4 mRNA
actually increased in diabetic conditions compared to
non-diabetic DRG neurons (quantification in figure le-
gend, Figure 4A-C).
We also examined the state of SDF-1 expression in the
DRG from normal and diabetic animals. We elected to
assess SDF-1 expression using mice expressing an SDF-
1-mRFP transgene generated in our laboratory [29].
Using an antibody against mRFP, we observed that DRG
neurons from HFD diabetic SDF-1-mRFP mice greatly
increased their expression of SDF-1 (Figure 4D and E)
compared to DRG neurons from RD mice (Figure 4F)
(quantification in figure legend, Figure 4D-F).alcium concentration in DRG sensory neurons in HFD-induced
cultured DRG sensory neurons from RD mice (A) and HFD mice (B)
M) and to capsaicin as positive control is also shown in RD (A) and
Figure 3 CXCR4 expression patterns in DRG sensory neurons. A-H: Confocal analysis of DRG isolated from non-diabetic CXCR4-eGFP mice
fed with regular diet (RD) showing co-localization of CXCR4-eGFP in green with either CGRP (red) (B and F) or IB4 (purple) (C and G). The majority
of DRG sensory neurons expressing CXCR4-eGFP are IB4 positive (C and G, arrows). Quantification: the percentage of CXCR4-eGFP positive cells
expressing IB4 was 32.8 ± 6.5% (n = 9) compared to the percentage of CXCR4-eGFP positive cells expressing CGRP 1.78 ± 1.78% (n = 7). Values
are expressed as means +/− SE% (p <0.001). I-P: Confocal analysis of DRG isolated from diabetic CXCR4-eGFP mice fed with High Fat Diet (HFD).
CXCR4-eGFP reporter gene transcriptional activity appeared to be decreased in HFD induced diabetic DRG (I-P). Quantification: the percentage
of IB4 positive DRG expressing CXCR4-EGFP in RD was 32.8 ± 6.5% (n = 9) compared to 1.0 ± 0.73% (n = 9) in HFD mice. Similarly, the percentage
of CGRP positive DRG neurons expressing CXCR4-eGFP was also reduced in HFD-induced mice compared to RD non diabetic mice. Indeed, the
percentage of CGRP positive DRG expressing CXCR4-EGFP in RD was 1.78 ± 1.78% (n = 7) compared with the 0.42 ± 0.42 (n = 9) in HFD DRG
neurons. Values are expressed as means ± SE% (p <0.001). (Magnification 20x (scale bar 250 μm) in A-D and I-L; magnification 40x (scale bar 50 μm)
in E-H and M-P). r: dorsal root.
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an ideal position to activate excitatory CXCR4 receptors
expressed by DRG neurons in PDN.
Inflammatory cell infiltration into diabetic DRG
In addition to the cell bodies of sensory neurons, DRGs
contain satellite glial cells, resident macrophages and it
has also been shown that they may contain infiltrating
leukocytes under inflammatory conditions [30,31]. All of
these cell types might potentially contribute to pain sig-
naling [25,28,31]. Chemokine signaling can promote in-
flammatory infiltration into the spinal cord and DRG
following nerve injury and in other models of neuro-
pathic pain [10,30]. We observed numerous CXCR4expressing inflammatory cells infiltrating into HFD dia-
betic DRG (Figure 5A and B). Characterization of the na-
ture of the inflammatory infiltrate revealed the presence
of CD3 positive T-cells in HFD DRG (Figure 5E-G). In
contrast, virtually no CD3 positive T-cells were noted in
control non-diabetic DRG (Figure 5H). Interestingly,
cells infiltrating into the diabetic DRG perineurium at
the site of the dorsal root entry zone were mainly CD68
positive macrophages (Figure 5I-K). Virtually no CD68
positive cells were noted in control no diabetic RD
DRG (Figure 5L). In contrast, the number of F4/80
positive macrophages in DRG under diabetic conditions
(Figure 5M and N) was the same compared to control
non-diabetic RD DRG (Figure 5O and P). However,
Figure 4 CXCR4 and SDF-1 expression in diabetic mouse DRG. A-C: Representative images of in situ hybridization experiments using an
antisense probe for CXCR4 receptors on DRG sections taken from diabetic mice fed with HFD (B) or control non-diabetic mice fed with RD (C). Arrows
indicate CXCR4 positive immune cells infiltrating the diabetic DRG. Arrowheads indicate neurons expressing CXCR4 chemokine receptors. In HFD DRG
expression of CXCR4 is in more neurons but at reduced levels per cells (B) compared to control DRG (C). Quantification: 15.652 ± 1.55 cells expressing
CXCR4 mRNA in HFD DRG compared with 7.833 ± 1.489 cells expressing CXCR4 mRNA in RD DRG. Values are expressed as means ± SD (p <0.001).
Sense probe control is shown for HFD conditions (A), * indicates DRG neurons, r indicates dorsal root. D-F: DRG from SDF-1- mRFP mice
diabetic fed with HFD (D and E) or non-diabetic mice fed with RD (F). Immunolabeling for mRFP reveals SDF-1 expression in neurons
(arrowheads) in HFD induced diabetic mice (D and E). E is higher magnification of panel in D. Expression of SDF-1-mRFP in diabetic mice
was observed in numerous neurons of many different sizes whereas only a few neurons exhibited low levels of chemokine expression in
normal mice. Quantification: 42.828 ± 8.05 cells expressing SDF-1 mRFP in HFD DRG (n = 3 animals, 10 sections from each animal) compared with
1.710 ± 1.21 cells expressing SDF-1 mRFP in RD DRG (n = 3 animals, 10 sections from each animal). Values are expressed as means ± SD (p <0.001). Asterisk
(*) indicates lack of neuronal SDF-1-mRFP expression in RD fed mice (F). (Magnification 20x (scale bar 250 μm) in D; magnification 40x (scale bar 50 μm)
in A, B, C, E, F).
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phology in diabetic DRG (Figure 5N) compared with
non-diabetic RD DRG (Figure 5P). F4/80 positive cells in
diabetic DRG assumed the morphology of activated
macrophages (Figure 5N). Finally, we did not observe
B220 positive B-cells in HFD-induced diabetic DRG or in
RD non-diabetic DRG (Figure. 5Q-S) using an antibody
against B220 which was clearly able to visualize B-cells in
the spleen (T). (Quantification in figure legend, Figure 5).
The presence of CXCR4 expressing immune cells with
the prevalence of CD3 positive T-cells in diabetic DRG




All animal experiments were approved by the Institu-
tional Animal Care and Use Committee at NorthwesternUniversity. Animals were housed with food and water ad
libitum and kept on 12-hours light cycle. Wild-type 8
weeks-old male C57BL/6 (Jackson Laboratories), 18 weeks
old db-db homozygous mice (Homozygous Lepr db, BKS.
Cg-Dock7m −/− Leprdb/J, Jackson Laboratories), 18 weeks
old heterozygous mice (Heterozygous Lepr db, BKS.Cg-
Dock7m +/− Leprdb/J, Jackson Laboratories), 8 weeks old
CXCR-4 eGFP mice and SDF-1-mRFP mice, generated in
our laboratory [29], were used in these studies.
High Fat Diet (HFD)-induced diabetes as a model of
Diabetes type II
HFD induces insulin resistance and is therefore used to
create rodent models of diabetes type-II [32]. Wild-type 8
weeks-old male C57BL/6 mice, CXCR-4 eGFP mice and
SDF-1-mRFP mice were fed with a 42% fat diet for 10
weeks. Control mice were fed with regular diet (11% fat
diet). After 10 weeks on HFD, Glucose Tolerance Test
Figure 5 CXCR4 positive inflammatory cells infiltrate diabetic DRG. Large influx of CXCR4-eGFP positive cells into HFD diabetic mice DRG
(A and B, asterisk). In contrast virtually no cells were observed in non-diabetic RD DRG (C and D). Quantification: 79.131 ± 15.03 CXCR4 expressing
inflammatory cells infiltrating into HFD DRG compared to 1.363 ± 0.82 in RD DRG. Characterization of the nature of the inflammatory infiltrate revealed
the presence of CD3 positive T-cells in diabetic DRG (E-G, arrows). On the contrary virtually no CD3 positive T-cells were noted in non-diabetic DRG
(F). Quantification: 39.132 ± 11.14 CD3 positive cells in HFD DRG compared to 1.945 ± 0.84 in RD DRG. Interestingly, cells infiltrating the diabetic
DRG at the dorsal root entry (arrows) were CD68 positive macrophages (I-K). Virtually no CD68 positive cells were noted in non-diabetic DRG
(L). Quantification: 16.333 ± 3.15 CD68 positive cells in HFD DRG compared to 0.205 ± 0.41 in RD DRG. The number of F4/80 positive macrophages
in diabetic DRG (M and N) was the same compared to non-diabetic DRG (O and P). Quantification: 26.615 ± 2.48 F4/80 positive cells in HFD DRG
compared to 26.558 ± 2.72 cells in RD DRG. However, F4/80 positive macrophages exhibited an altered morphology in diabetic DRG (N, arrows)
compared with non-diabetic DRG (P, arrows). Indeed, F4/80 positive cells in diabetic DRG assumed the morphology of activated macrophages
(N, arrows). No B220 positive B-cells were noted in diabetic DRG (Q-S) using an antibody against B220 able to visualize B-cells in the spleen
(T). (Magnification 10X, scale bar 500 μm: E, I, Q; 20x, scale bar 250 μm: A-D, F, J, M, O, R; 40X scale bar 50 μm: G, H, K, L, N, P, S, T).
r: dorsal root. Values expressed as means ± SD (p <0.001).
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mice, after fasting for 12 hours, were injected with a 45%
D-glucose solution (2mg glucose/1g animal body weight).
Blood glucose is measured immediately before and 30, 60,
and 120 minutes after glucose injection using an One-
Touch UltraMini glucose meter and OneTouch Ultra
test strips.Behavioral testing
Von Frey behavioral studies were performed as previ-
ously described [9,19,20,33,34]. Briefly, mice were placed
on a metal mesh floor and covered with a transparent
plastic dome where the animal rested quietly after an
initial few minutes of exploration. Animals were habitu-
ated to this testing apparatus for 15 minutes a day, two
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acclimation, each filament was applied to the glabrous
side of the hind paw. Mechanical stimuli were applied
with seven filaments, each differing in the bending force
delivered (10, 20, 40, 60, 80, 100, and 120 mN), but each
fitted a flat tip and a fixed diameter of 0.2 mm. The
force equivalence of mN to grams is: 100 mN = 10.197
grams. The filaments were tested in order of ascending
force, with each filament delivered for 1 second. The
interstimulus interval was 10–15 seconds [34].Statistical analysis
The incidence of foot withdrawal was expressed as a per-
centage of six applications of each filament as a function
of force. A Hill equation was fitted to the function (Origin
version 6.0, Microcal Software) relating the percentage of
indentations eliciting a withdrawal to the force of indenta-
tion. From this equation, the threshold force was obtained
and defined as the force corresponding to a 50% with-
drawal rate [34]. The GB-Stat School Pack software (Dy-
namic Microsystem) was used to statistically evaluate all
data. The one-way analysis of variance (ANOVA) with a
Dunnett’s Multiple Comparison test was used to analyze
difference between multiple experimental groups. A prob-
ability level of .05 indicates significance.CXCR4 chemokine receptor blocker administration
The highly specific CXCR4 antagonist, AMD3100 (Sigma
(St Louis, MO, USA), was used for the all the experiments.
The CXCR4 chemokine receptor antagonist was adminis-
tered to HFD induced diabetic and control non-diabetic
mice 10 weeks after diet, to 18 weeks old diabetic homo-
zygous C57BLKS db/db (db/db) mice and control hetero-
zygous C57BLKS db/db (db het) mice. The drug was
freshly prepared in saline on the day of the experiment at
a concentration of 5 mg/kg and given as a one-time intra-
peritoneal (i.p.) injection.Preparation of acutely cultured dorsal root ganglion neurons
DRG sensory neurons from HFD-induced diabetic wild-
type mice were acutely dissociated as previously de-
scribed [20] after 10 weeks of HFD. Wild type mice on
regular diet were used as controls. Briefly, DRG neurons
were acutely dissociated via collagenase 4 (1 μg/ml)
and papain (30 U/ml), Worthington Biochemical
Corp, Lakewood, NJ) digestion. Cells were plated on
poly-L-lysine and laminin (20 μg/ml) coated glass
coverslips and cultured at 37 degrees Celsius with 5%
CO2, for 48 hrs in adult neurogenic medium: F12
with L-glutamine, 0.5% FBS, 1xN2 (Life Techonologies),
penicillin (100 μg/ml) and streptomycin (100 U/ml).Intracellular calcium imaging in vitro
The response of acutely cultured DRG neurons to the
chemokines SDF-1 and MCP-1 (500 ng/ml R&D Sys-
tems) were recorded using intracellular calcium im-
agining following a standard protocol previously used
in our laboratory [20]. Briefly, acutely cultured DRG
cells were loaded with fura-2 AM (3uM, Invitrogen,
Carlsbad, CA) for 25 minutes at room temperature
in a balanced salt solution (BSS) [NaCl (140 mM),
Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose
(10 mM), KCl (5 mM)]. The cells were rinsed with the
BSS and mounted onto a chamber that was placed onto
the inverted microscope and continuously perfused with
BSS at a rate of 2 ml/min. Intracellular calcium ([Ca2+]i)
was measured by digital video microfluorometry with an
intensified CCD camera coupled to a microscope and
MetaFluor software. Cells were illuminated with a
150W xenon arc lamp, and the excitation wave-
lengths of the fura-2 (340/380 nm) were selected by
a filter changer. Chemokines were applied for two
minutes directly into the coverslip bathing solution
after the perfusion was stopped. If no response was
seen within 1 minute, the chemokine was washed
out. For all experiments, SDF-1 (500 ng/ml, R&D
Systems) and MCP-1 (500 ng/ml, R&D Systems),
capsaicin (100 nM), high K + (50 mM) and ATP (100 μM)
were added to the cells.Statistical analysis
The significance of differences between the control group,
and the various treatment groups were statistically ana-
lyzed. Within each treatment group, post-drug administra-
tion means were compared with the baseline/control
values by analysis of variance (ANOVA).Immunohistochemical labeling: Immunofluorescence
Adult CXCR4-eGFP mice were deeply anesthetized with
isoflurane and transcardially perfused with saline followed
by 4% paraformaldehyde. Lumbar ganglia were removed
and post fixed for 4 hours. Sagittal sections of the DRG
were serially cut at 20 μm onto Super Frost microscope
slides (Fisher Scientific, Pittsburgh PA). At least 6 sections
were obtained for immunocytological analysis per DRG.
Slides were incubated with blocking buffer (3% BSA/3%
horse serum/0.4% Triton-X; Fisher Scientific, Pittsburgh
PA) for 1 hour, followed by overnight incubation with pri-
mary antibody. We used the following antibodies on
CXCR4-eGFP DRG section: I-isolectin B4 (IB4-conjugated
647 from Invitrogen, used at 1:100 dilution) and Calci-
tonin gene-related peptide (CGRP rabbit polyclonal Ab
from Abcam, used at 1:4000). Slides were washed in PBS
three times for 5 minutes each and cover slipped with a
Vectasheld.
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Tissue sections were analyzed by confocal microscopy
for co-expression of CXCR4 chemokine receptor eGFP
and Isolectin (IB4) or Calcitonin gene-related peptide
(CGRP) using confocal microscopy.
Statistical analysis
The proportions of immune-reactive neurons were de-
termined from the total number of CXCR4-eGFP positive
neuron present in a tissue section. At least 5000 neuronal
profiles from six animals (minimum of 625 cells per gan-
glia) were quantified for each cell type in the single neu-
ronal marker study and for each combination of cellular
markers. Data are represented as means ± SE%.
Peroxidase-diaminobenzidine (DAB) immunolabeling
Wild-type 8 weeks-old male C57BL/6 mice and 8
weeks-old male SDF-1-mRFP mice, HFD-induced dia-
betic and control RD non-diabetic mice were deeply
anesthetized with isoflurane and trans-cardially perfused
with saline followed by 4% paraformaldehyde. Lumbar
ganglia were removed and post fixed for 4 hours. Sagittal
sections of the DRG were serially cut at 20 μm onto Super
Frost microscope slides (Fisher Scientific, Pittsburgh PA).
At least 6 sections were obtained for immune-cytological
analysis per DRG. Sections were incubated with 3% hydro-
gen peroxidase for 30 minutes at room temperature to
block endogenous peroxidase. Slides were then incubated
with blocking buffer (5% donkey serum) for 1 hour,
followed by overnight incubation with primary antibody.
We used the following antibodies on DRG sections: anti-
CD3 rabbit polyclonal antibody from Dako, used at 1:500;
anti-CD68 rabbit polyclonal antibody from Abcam, used
at 1:500; anti-F4/80 rat antibody from eBiosciences, used
at 1:500 and anti-B220 rat antibody from BD Biosciences,
used at 1:1000. Slides were washed three times in PBS for
5 minutes each and then incubated with secondary bio-
tinylated antibody for 1 hour at room temperature. Colori-
metric reaction was carried out using the ABC kit and
streptavidin-HRP and DAB system from Vector Labora-
tories. Additionally, we used antibodies against RFP on
DRG from SDF-1-RFP mice to detect chemokine SDF-1
(anti-RFP rabbit polyclonal Ab from Abcam, used at
1:1000). In this set of experiments, the colorimetric
reaction was carried out using SG blue (Sk-4700), by
Vector Laboratories.
Statistical analysis
The images of stained tissues were captured on a BX51
Olympus microscope using a 20x and 40x objectives
with an Olympus DP70 digital camera controlled by ana-
lysis software (Soft Imaging System). Image acquisition
was performed with the following fixed color settings:
red = 0.36, green = 0.92, blue = 0.85, offset = 504, andexposure time of 6.8 milliseconds. At least 10 sections
were analyzed from each mouse (3 HFD diabetic mice
and 3 RD control mice). Counts were performed on a
standardized area of 200 μm x 300 μm. The one-way
analysis of variance (ANOVA) test was used to analyze
difference between experimental groups. A probability
level of .05 indicates significance.
In situ hybridization
In situ hybridization for chemokine receptor CXCR4
mRNA was performed using digoxigenin labeled ribo-
probes. Wild-type 8 weeks-old male C57BL/6 (Jackson
Laboratories) HFD induced diabetic and RD non dia-
betic DRGs were rapidly removed, embedded in OCT
compound (Tissue Tek, Ted Pella, Inc., Redding, CA)
and frozen. Sections were cut serially at 12 μm. The
CXCR4 probe was generated as described previously
[19,20]. Briefly, the rat CXCR4 cDNA was cloned as de-
scribed [19,20] and a 870-bp SacI/ClaI fragment from
CXCR4/pcDNA3.1 construct was used as CXCR4 ribop-
robe, which can cross-react with mouse CXCR4. The
template was linearized with XbaI to generate an anti-
sense probe by using SP6 polymerase. The sense probe
was linearized with HindIII by using T7 polymerase. In
situ hybridization for CXCR4 mRNA was performed by
using digoxigenin-labeled riboprobes (Roche Applied
Science), as previously describe [19,20].
Statistical analysis
The images of stained tissues were captured on a BX51
Olympus microscope using a 20x and 40x objectives with
an Olympus DP70 digital camera controlled by analysis
software (Soft Imaging System). Image acquisition was per-
formed with the following fixed color settings: red = 0.36,
green = 0.92, blue = 0.85, offset = 504, and exposure time
of 6.8 milliseconds. At least 10 sections were analyzed
from each mouse (3 HFD diabetic mice and 3 RD con-
trol mice). Counts were performed on a standardized
area of 200 μm × 300 μm. Experiments were carried out
in duplicates. The one-way analysis of variance (ANOVA)
test was used to analyze difference between experimental
groups. A probability level of .05 indicates significance.
Discussion
CXCR4/SDF-1 signaling has been implicated in the patho-
genesis of neuropathic pain in a subset of animal models
as illustrated in previous reports from our own and other
laboratories [19,20]. Importantly, CXCR4 expression is
increased in a peripheral nerve microarray analysis from
diabetic patients with progressive diabetic neuropathy
[22], implicating CXCR4/SDF-1 signaling in the patho-
genesis of diabetic neuropathy in humans. The present
studies were designed to investigate a potential role for
CXCR4/SDF-1 signaling in the pathogenesis of PDN.
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AMD3100 reversed PDN in two animal models of type
II diabetes indicating that ongoing CXCR4/SDF-1 sig-
naling is necessary for the manifestation of PDN. Fur-
thermore, SDF-1 increased [Ca2+]i in DRG neurons
from diabetic mice to a greater extent than in normal
mice, suggesting increased CXCR4 receptor signaling in
DRG neurons in the context of PDN. SDF-1 has also
been shown to promote inflammatory cell infiltration
into the DRG [10,30]. Indeed, we observed increased
SDF-1 expression in DRG neurons and a massive influx
of inflammatory cells into the DRG of diabetic animals
that may have important implications for the generation
of pain behaviors under these circumstances. Overall
these results suggest that CXCR4/SDF-1 signaling plays
a critical role in the pathogenesis of PDN by inducing
excitatory effects on DRG neurons and recruiting in-
flammatory cells into diabetic DRG.
The present studies demonstrate for the first time that
excitatory CXCR4/SDF-1 signaling in DRG neurons plays
a critical role in the pathogenesis of PDN. Previous studies
from our laboratory and others have demonstrated that
SDF-1 and other chemokines can directly excite DRG
neurons [20,25,29,35,36]. The pronociceptive effects of
chemokines and their receptors include the induction of
hyperexcitability of neurons through transactivation of
transient receptor potential cation channel subfamily V
member 1 (TRPV1) and other ion channels [37,38]. This
process has been demonstrated on cultured and previ-
ously injured adult DRG sensory neurons [37,38]. We
have now demonstrated that the specific CXCR4 antag-
onist AMD3100 reversed PDN in two animal models of
type II diabetes indicating that ongoing CXCR4/SDF-1
signaling is necessary for the manifestation of PDN. As
activation of CXCR4 chemokine receptors expressed by
DRG neurons produces excitation [18], it is likely on-
going activation of CXCR4 receptors by SDF-1 released
within the DRG contributes to the ectopic excitability of
these neurons and produces AMD3100 reversible tactile
hyperalgesia.
[Ca2+]i imaging experiments clearly demonstrated in-
creased calcium mobilization in response to SDF-1 in
cultured diabetic DRG neurons compared non diabetic
control animals. Our laboratory and others have previ-
ously shown that activation of CXCR4 receptors by its
ligand SDF-1 excites DRG neurons. Increased [Ca2+] i
can be used as a readout of DRG neuron hyperexcitability
in animal models of neuropathic pain [20,25,36]. There-
fore, these data are consistent with the possibility that
CXCR4/SDF-1 signaling plays a critical role in the patho-
genesis of PDN by inducing excitatory effects directly on
DRG neurons. Additionally, these data provide evidence
of a considerable degree of CXCR4 receptor upregulation
in acutely cultured diabetic DRG neurons. Interestingly,however, we actually observed a decline in CXCR4 gene
transcriptional activity in vivo in diabetic CXCR4-eGFP
mice. These results appear to contradict one another.
However, an explanation was provided by further studies
using in situ hybridization to detect CXCR4 mRNA ex-
pression in the DRG. We observed two types of CXCR4
expressing neurons in the DRG of normal mice. One
population expressed very high levels of CXCR4 mRNA
and the other group expressed lower levels. In diabetic
mice we observed that the population of neurons that
expressed very high levels of CXCR4 receptors was greatly
reduced. In contrast the total number of neurons express-
ing CXCR4 receptors was increased. It is likely that we are
only able to detect the population of neurons with high
levels of CXCR4 expression using CXCR4-eGFP trans-
genic mice. This would explain why the number of
CXCR4-eGFP cells is found to be reduced in diabetic
CXCR4-eGFP transgenic mice, but we detect an increased
number of cells expressing functional CXCR4 receptors
using in situ hybridization experiments and [Ca2+]i im-
aging assays. The reason for this overall shift in the pat-
tern of DRG neurons expressing CXCR4 receptors in
diabetic mice is elusive at this point. However, we did
note that DRG neurons from diabetic mice exhibited
greatly increased levels of SDF-1.
We have demonstrated that SDF-1 can be released
from DRG neurons [10,21]. Hence SDF-1 would be in a
position to activate CXCR4 receptors expressed within the
DRG of diabetic mice, which would be predicted to in-
crease their excitability. Therefore it is possible that up-
regulated expression of excitatory CXCR4 signaling
within the DRG might be one factor driving increased
excitability of these neurons in PDN.
Overall, these results are particularly interesting in
light of recent publications using gene arrays to profile
sural nerve samples from PDN patients, which reported
that CXCR4 chemokine receptor expression was up-
regulated in these samples [22]. Hence, the data from
both mice and humans suggests the presence of up-
regulated excitatory CXCR4 signaling by DRG neurons
in association with PDN. These observations raise ques-
tions that now need further investigation, for example to
determine which subtypes of sensory neurons are the
major elements responsible for SDF-1/CXCR4 mediated
neuropathic pain in diabetes.
During embryonic development DRG sensory neurons
differentiate into three primary subtypes: nociceptors,
mechanoreceptors and proprioceptors. In the DRG,
these are characterized by the expression of the neuro-
trophin receptors TrkA, TrkB and TrkC, respectively
[39]. During perinatal development nociceptors further
differentiate into peptidergic (CGRP positive) and non-
peptidergic (IB4 positive) [26]. We demonstrated that high
levels of CXCR4 receptors, as determined using CXCR4-
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nociceptive neurons. This observation is of particular
interest in light of prior publications demonstrating that
peripheral inflammation selectively increases TRPV1
function in IB4 positive sensory neurons in mouse models
of neuropathic pain [40,41]. The enhanced responsiveness
of IB4 binding neurons in the setting of inflammatory
hyperalgesia could be mediated by CXCR4/SDF-1 signal-
ing and be relevant in the pathogenesis of PDN. Our in
situ hybridization studies also revealed the existence of a
second population of DRG neurons, which express lower
levels of CXCR4 receptors although we did not identify
the properties of this neuronal subtype. Nevertheless, exci-
tatory effects of CXCR4 activation in these neurons may
also contribute to pain in diabetic mice.
In addition to their pronociceptive effects on DRG
neurons chemokines and their receptors are important
in the recruitment of leukocytes. The observed recruit-
ment of numerous inflammatory cells into diabetic DRG
suggests a critical role for inflammation in the pathogen-
esis of PDN. Immune cells can certainly secrete numerous
algogenic factors, which may also have direct excitatory ef-
fects on DRG neurons or may sensitize DRG neurons to
the excitatory effects of SDF-1 or other mediators [10,14].
SDF-1 has been shown to promote inflammatory cell infil-
tration into the DRG [10,30]. Hence SDF-1 released from
diabetic DRG neurons may well influence the influx of in-
flammatory cells into DRG which may have important im-
plications for the generation of pain behaviors under these
circumstances.
The role of inflammation in the pathogenesis of PDN
has been proposed elsewhere [42]. Specifically, inflam-
matory cytokines such as interleukins IL-6, IL-2, and
tumor necrosis factor-α (TNF-α) are elevated in hyper-
glycemia, suggesting that a chronic low grade inflamma-
tory state exists in patients with diabetes [43,44]. It has
been observed that diabetic patients with higher plasma
levels of TNF-α have a greater risk of developing PDN
[43,45,46]. Moreover, compared with diabetic patients
who have painless neuropathy those with PDN have been
shown to have higher levels of C-reactive protein, con-
sidered to be a biomarker for any inflammatory process
[47]. Recently, inflammatory mediators, including TNF-α,
interleukin-1, 6, 13 and 17, chemokines such as MIP-1α,
RANTES and fractalkine, have been found to be increased
in the DRG of Zucker diabetic fatty (ZDF) rats, an estab-
lished model for type II diabetes [48]. Additionally, mole-
cules generated as the result of hyperglycemia including
Advanced Glycolation End Products (AGE) and their re-
ceptor (RAGE) are considered important in the pathogen-
esis of PDN [49-52] and have been implicated in signaling
pathways that induce transcription of proinflammatory
genes [51]. In particular, chemokine expression is one im-
portant downstream target for both TNF-α and RAGEsignaling. The present study provides additional support
for a role of inflammation in the pathogenesis PDN pro-
viding a novel theoretical concept and also a new thera-
peutic target for the treatment of PDN.
In conclusion, these studies establish CXCR4/SDF-1
chemokine signaling as a new candidate responsible for
the manifestation of PDN. The data suggest a mechanism
as to how ongoing sensory neuron excitability could be in-
creased in order to induce and maintain neuropathic pain
in diabetes. This concept is that chemokine signaling has
a fundamental role in in producing increased excitability
of sensory neurons during the transition from physio-
logical to neuropathic pain in diabetes, as well as its subse-
quent maintenance. This is something that has not been
previously appreciated with respect to PDN. Furthermore,
SDF-1 could potentially play a crucial role in both recruit-
ing inflammatory cells and producing direct excitatory ef-
fects on DRG neurons thereby coordinating the interaction
between peripheral neurons and immune cells. Hence,
targeting CXCR4/SDF-1 signaling may lead to advanced
therapeutic approaches for the treatment of PDN. This
novel and more targeted therapeutic intervention has
advantages over existing and currently available thera-
peutic approaches which aim only to reduce symptoms
generally by suppressing neuronal activity and are not
particularly effective. In contrast, modulation of proal-
gesic chemokine signaling provides an opportunity for
disease modification by inhibiting inflammatory process
and neurobiological alterations that support the devel-
opment of persistent pain.
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